Literature DB >> 24154876

TRAF4 is a critical molecule for Akt activation in lung cancer.

Wei Li1, Cong Peng, Mee-Hyun Lee, DoYoung Lim, Feng Zhu, Yang Fu, Ge Yang, Yuqiao Sheng, Lanbo Xiao, Xin Dong, WeiYa Ma, Ann M Bode, Ya Cao, Zigang Dong.   

Abstract

TRAF4 is an adapter protein overexpressed in certain cancers, but its contributions to tumorigenesis are unclear. In lung cancer cells and primary lung tumors, we found that TRAF4 is overexpressed. RNA interference-mediated attenuation of TRAF4 expression blunted the malignant phenotype in this setting, exerting inhibitory effects on cell proliferation, anchorage-independent growth, and tumor development in a xenograft mouse model. Unexpectedly, we discovered that TRAF4, but not Skp2, was required for activation of the pivotal cell survival kinase Akt through ubiquitination. Furthermore, TRAF4 attenuation impaired glucose metabolism by inhibiting expression of Glut1 and HK2 mediated by the Akt pathway. Overall, our work suggests that TRAF4 offers a candidate molecular target for lung cancer prevention and therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24154876      PMCID: PMC3856436          DOI: 10.1158/0008-5472.CAN-13-0913

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  TRAF4 overexpression is a common characteristic of human carcinomas.

Authors:  S Camilleri-Broët; I Cremer; B Marmey; E Comperat; F Viguié; J Audouin; M-C Rio; W-H Fridman; C Sautès-Fridman; C H Régnier
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

Review 2.  TRAF4, the unique family member.

Authors:  Valérie Kedinger; Marie-Christine Rio
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

3.  The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis.

Authors:  Regan M Memmott; Phillip A Dennis
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

4.  Ubiquitin-conjugating enzyme Ubc13 is a critical component of TNF receptor-associated factor (TRAF)-mediated inflammatory responses.

Authors:  Toru Fukushima; Shu-ichi Matsuzawa; Christina L Kress; Jean Marie Bruey; Maryla Krajewska; Sophie Lefebvre; Juan M Zapata; Ze'ev Ronai; John C Reed
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-02       Impact factor: 11.205

Review 5.  Mitochondria and cancer: Warburg addressed.

Authors:  D C Wallace
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2005

Review 6.  Epidermal growth factor receptor mutations in lung cancer.

Authors:  Sreenath V Sharma; Daphne W Bell; Jeffrey Settleman; Daniel A Haber
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

7.  The E3 ligase TRAF6 regulates Akt ubiquitination and activation.

Authors:  Wei-Lei Yang; Jing Wang; Chia-Hsin Chan; Szu-Wei Lee; Alejandro D Campos; Betty Lamothe; Lana Hur; Brian C Grabiner; Xin Lin; Bryant G Darnay; Hui-Kuan Lin
Journal:  Science       Date:  2009-08-28       Impact factor: 47.728

Review 8.  Targeting the phosphoinositide 3-kinase pathway in cancer.

Authors:  Pixu Liu; Hailing Cheng; Thomas M Roberts; Jean J Zhao
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

9.  E2 interaction and dimerization in the crystal structure of TRAF6.

Authors:  Qian Yin; Su-Chang Lin; Betty Lamothe; Miao Lu; Yu-Chih Lo; Gregory Hura; Lixin Zheng; Rebecca L Rich; Alejandro D Campos; David G Myszka; Michael J Lenardo; Bryant G Darnay; Hao Wu
Journal:  Nat Struct Mol Biol       Date:  2009-05-24       Impact factor: 15.369

Review 10.  AKT/PKB signaling: navigating downstream.

Authors:  Brendan D Manning; Lewis C Cantley
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

View more
  50 in total

1.  Novel interaction of antioxidant-1 with TRAF4: role in inflammatory responses in endothelial cells.

Authors:  Archita Das; Varadarajan Sudhahar; Masuko Ushio-Fukai; Tohru Fukai
Journal:  Am J Physiol Cell Physiol       Date:  2019-09-25       Impact factor: 4.249

2.  Understanding the unimodal distributions of cancer occurrence rates: it takes two factors for a cancer to occur.

Authors:  Shuang Qiu; Zheng An; Renbo Tan; Ping-An He; Jingjing Jing; Hongxia Li; Shuang Wu; Ying Xu
Journal:  Brief Bioinform       Date:  2021-07-20       Impact factor: 11.622

3.  TRAF4 promotes the growth and invasion of colon cancer through the Wnt/β-catenin pathway.

Authors:  Ke Yang; Feng Wang; Jian-Jun Han
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  Upregulated expression of ILF2 in non-small cell lung cancer is associated with tumor cell proliferation and poor prognosis.

Authors:  Tingting Ni; Guoxin Mao; Qun Xue; Yifei Liu; Buyou Chen; Xuefan Cui; Liting Lv; Liangliang Jia; Yuchan Wang; Lili Ji
Journal:  J Mol Histol       Date:  2015-06-10       Impact factor: 2.611

5.  TRAF4 binds to the juxtamembrane region of EGFR directly and promotes kinase activation.

Authors:  Gang Cai; Liang Zhu; Xing Chen; Kevin Sun; Caini Liu; Ganes C Sen; George R Stark; Jun Qin; Xiaoxia Li
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-23       Impact factor: 11.205

6.  TRAF4 enhances oral squamous cell carcinoma cell growth, invasion and migration by Wnt-β-catenin signaling pathway.

Authors:  Jianbin Yang; Dongyi Wei; Weixin Wang; Baohong Shen; Suling Xu; Yuan Cao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Molecular basis for unique specificity of human TRAF4 for platelets GPIbβ and GPVI.

Authors:  Chang Min Kim; Young-Jin Son; Sunghwan Kim; Seo Yun Kim; Hyun Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-10       Impact factor: 11.205

8.  TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis.

Authors:  Ramesh Singh; Dileep Karri; Hong Shen; Jiangyong Shao; Subhamoy Dasgupta; Shixia Huang; Dean P Edwards; Michael M Ittmann; Bert W O'Malley; Ping Yi
Journal:  J Clin Invest       Date:  2018-06-18       Impact factor: 14.808

9.  Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin.

Authors:  Xinfang Yu; Ruike Wang; Yangnan Zhang; Li Zhou; Wei Wang; Haidan Liu; Wei Li
Journal:  Oncogene       Date:  2019-08-21       Impact factor: 9.867

10.  miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.

Authors:  Sonali Sharma; Gabriela Mladonicka Pavlasova; Vaclav Seda; Katerina Amruz Cerna; Eva Vojackova; Daniel Filip; Laura Ondrisova; Veronika Sandova; Lenka Kostalova; Pedro F Zeni; Marek Borsky; Jan Oppelt; Kvetoslava Liskova; Leos Kren; Andrea Janikova; Sarka Pospisilova; Stacey M Fernandes; Medhat Shehata; Laura Z Rassenti; Ulrich Jaeger; Michael Doubek; Matthew S Davids; Jennifer R Brown; Jiri Mayer; Thomas J Kipps; Marek Mraz
Journal:  Blood       Date:  2021-05-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.